Li-Tzong Chen

15PUBLICATIONS

108CO-AUTHORS

Predictive and prognostic markersCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCheminformatics and quantitative structure-activity relationships

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (15)

Sort by Publication Date:

|May 21, 2026

A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC.

|Feb 26, 2026

Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors.

Chien-Tsung Liu, Yung-Yeh Su, Nai-Jung Chiang

|Oct 21, 2025

Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial.

Muh-Hwa Yang, Shang-Yin Wu, I-Wei Ho

|Sep 30, 2025

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

James J Harding, Do-Youn Oh, Teresa Macarulla Mercade

|Jul 07, 2025

Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition.

Tzu-Lei Kuo, Ya-Chin Hou, Yan-Shen Shan

|Jun 13, 2025

GFH018 and Toripalimab Combination Therapy for Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: Results from a Phase Ib/II Study.

Lin-Quan Tang, Sai-Lan Liu, Muh-Hwa Yang

Pageof 3

Frequent Collaborators

Yan-Shen Shan

Li-Yuan Bai

Yung-Yeh Su

Nai-Jung Chiang

Jen-Shi Chen

James J Harding

Mitesh J Borad

Daw-Yang Hwang

Hui-Jen Tsai

Do-Youn Oh

Frequent Collaborators

Yan-Shen Shan

Li-Yuan Bai

Yung-Yeh Su

Nai-Jung Chiang